Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease

Annals of the Rheumatic Diseases

Volumn 71, Issue 9, 2012, Pages 1591-1592

  Ugurlu, Serdal ^a   Ucar, Didar ^a   Seyahi, Emire ^a   Hatemi, Gulen ^a   Yurdakul, Sebahattin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CANAKINUMAB; CYCLOSPORIN A; INFLIXIMAB; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ADOLESCENT; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; EYE DISEASE; EYE EXAMINATION; FEMALE; FEVER; HUMAN; HYPOPYON; LETTER; OPTIC NERVE ATROPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RETINA VASCULITIS; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; DRUG ANTAGONISM; PATHOPHYSIOLOGY;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HUMANS; INTERLEUKIN-1BETA;

EID: 84864873192     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201383     Document Type: Letter

References (6)

1. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60-76. (Pubitemid 36139801)
2. Kötter I, Hamuryudan V, Oztürk ZE, et al. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 2010;22:278-83.
3. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41. (Pubitemid 47061701)
4. Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13:R202.
5. Botsios C, Sfriso P, Furlan A, et al. Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008;149:284-6.
6. Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β- regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 2012;71:563-6.